Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enasidenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 known ✓ | P48735 | 13/20 | 1.00 |
| ▸ | IDH1 | O75874 | 13/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.91 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.91 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.91 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.91 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.91 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.91 |
| ▸ | KDR | P35968 | 1/20 | 0.91 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enasidenib SCHEMBL29773080 | 1.00 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL29360046 | 0.95 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL15102202 | 0.95 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15102425 | 0.92 | IDH1 (0.93) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15102444 | 0.92 | IDH1 (0.93) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL17891027 | 0.89 | IDH2 (0.87) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774517 | 0.88 | IDH2 (0.85) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15102582 | 0.88 | IDH2 (0.85) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL29560993 | 0.88 | IDH2 (0.85) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15102481 | 0.88 | IDH1 (0.85) | IDH2IDH1ABCB11ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727933-A1 | COMBINATION THERAPY METHODS FOR TREATING TP53-Y220C MUTANT AND TP53 WILDTYPE LEUKEMIAS | Board of Regents, The University of Texas System (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260085059-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2026-03-26 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260014183-A1 | LOW-INTENSITY TREATMENT OF HEMATOLOGICAL DISORDERS | JAZZ PHARMACEUTICALS THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | claimed |
| EP-4014047-B1 | OGDH INHIBITORS FOR USE IN THE TREATMENT OF CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-19 | — | — | EP | claimed |
| EP-4623930-A2 | METHODS FOR IDENTIFYING LILRB-BLOCKING ANTIBODIES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-01 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-20250161478-A1 | LINKER PAYLOADS AND CONJUGATES THEREOF | GLYKOS FINLAND OY (FI) | 2025-05-22 | — | — | US | claimed |
| EP-4553085-A1 | ISOLATED ANTIGEN-BINDING PROTEIN AND USE THEREOF | Hangzhou Sumgen Biotech Co., Ltd. (CN) | 2025-05-14 | — | — | EP | claimed |
| WO-2018048847-A1 | TABLET COMPOSITIONS | CELGENE CORPORATION (US) | 2018-03-15 | — | — | WO | claimed |
| US-20180064715-A1 | TABLET COMPOSITIONS | SERVIER PHARMACEUTICALS LLC | 2018-03-08 | — | — | US | claimed |
| US-9889137-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | claimed |
| US-20170305885-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-10-26 | — | — | US | claimed |
| US-20170266193-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-09-21 | — | — | US | claimed |
| US-9738625-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | claimed |
| EP-3200800-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2017-08-09 | — | — | EP | claimed |
| US-9694013-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | claimed |
| WO-2016053850-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2016-04-07 | — | — | WO | claimed |
| US-20160089374-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-03-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160089374-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | NFATC1, BCL6, MCTS1 | IDH2 22/4885IDH1 14/4885ABCB11 4471/4885 |
| US-20250161478-A1 | LINKER PAYLOADS AND CONJUGATES THEREOF | PAICS, CD47, CD44 | IDH2 2176/4885IDH1 920/4885ABCB11 254/4885 |
| US-20170266193-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | NFATC1, BCL6, MCTS1 | IDH2 22/4885IDH1 14/4885ABCB11 4471/4885 |
| US-20260014183-A1 | LOW-INTENSITY TREATMENT OF HEMATOLOGICAL DISORDERS | MCL1, BCL9, BCL9L | IDH2 1491/4885IDH1 1401/4885ABCB11 1316/4885 |
| US-20170305885-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH2 123/4885IDH1 238/4885ABCB11 3369/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | IDH2 42/4885IDH1 39/4885ABCB11 3749/4885 |
| US-20180064715-A1 | TABLET COMPOSITIONS | TPP2, HTR3D, SLC5A2 | IDH2 3643/4885IDH1 2222/4885ABCB11 433/4885 |
| US-20260085059-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH2, IDH3B, IDH1 | IDH2 1/4885IDH1 3/4885ABCB11 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.